Abstract

BackgroundTransplantation improves survival and the quality of life of patients with end-stage organ failure. Infection, due to surgical issues, host factors such as diabetes, immunosuppression, and hypogammaglobulinemia, is a major post-transplant complication. Clinical outcomes of prophylaxis or treatment of hypogammaglobulinemia in solid organ transplant recipients are not well established and are in need of further study.Methods/designWe will conduct a systematic review of studies investigating clinically relevant outcomes of immunoglobulin use either as prophylaxis or treatment of hypogammaglobulinemia after solid organ transplantation. Both randomized and non-randomized studies (excluding case reports and case series of less than 20 subjects) will be included. Outcomes of interest will include the overall rate of infection, hospital admission, hospital length of stay, intensive care unit admission, 1-year all-cause mortality, incidence of acute organ rejection, allograft survival within 1 year, and adverse events. We will search MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, Transplant library, and the International Clinical Trials Registry Platform for randomized and non-randomized studies on adult solid organ transplant patients who received prophylactic immunoglobulin or immunoglobulin treatment. Two reviewers will conduct all screening and data collection independently. We will assess study level of risk of bias using the Cochrane Risk of Bias Assessment Tool for randomized controlled trials and for non-randomized studies. If meta-analysis of outcome data is deemed appropriate, we will use random effects models to combine data for continuous and dichotomous measures.DiscussionThe results of this systematic review may inform guideline development for measuring immunoglobulin level and use of immunoglobulin in solid organ transplant patients and highlight areas for further research.Systematic review registrationPROSPERO CRD42015017620Electronic supplementary materialThe online version of this article (doi:10.1186/s13643-015-0156-6) contains supplementary material, which is available to authorized users.

Highlights

  • Transplantation improves survival and the quality of life of patients with end-stage organ failure

  • Hypogammaglobulinemia (gamma-immunoglobulin (IgG)

  • This study showed that increasing immunoglobulin levels with Intravenous immunoglobulin (IVIG) did not have any impact on survival

Read more

Summary

Discussion

We will assess the treatment outcome of hypogammaglobulinemia post solid organ transplantation. Studies may concentrate on a particular type of solid organ transplantation, in which case the data will be pooled and analyzed within the same type of transplantation. This may limit the generalizability to other types of solid organ transplantation but may provide for a better-focused interpretation. Our systematic review will provide important insights into the effects of immunoglobulin replacement therapy or prophylactic therapy in solid organ transplant recipients. JC, BH, and GK will perform data interpretation and manuscript preparation. Author details 1Division of Infectious Diseases, Department of Medicine, University of Ottawa, Ottawa, Canada.

Background
Methods
Study design
Findings
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call